NAC before half-matched stem cell transplant for aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether taking a medication called N-acetylcysteine (NAC) before a half-matched stem cell transplant can help your body make new platelets faster. Platelets are blood cells that help prevent bleeding, which is a common problem after transplant for severe aplastic anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 50 years old.
- You have severe aplastic anemia (a condition where your bone marrow doesn't make enough blood cells) and are planning your first stem cell transplant from a half-matched donor.
- Your overall health is good enough for transplant (no major organ damage or uncontrolled infections).
- You are not allergic to N-acetylcysteine (NAC) and have no history of asthma.
- You are not pregnant or breastfeeding.
- You agree to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether N-acetylcysteine (NAC), a common supplement, can help your bone marrow recover faster after a stem cell transplant for severe aplastic anemia. If you qualify, you'll receive NAC alongside your standard transplant care.
This trial tests a new approach: first, you receive a specially engineered immune cell treatment (CD7 CAR-T) to help prepare your body, then a stem cell transplant from a relative. It's designed for people with severe aplastic anemia who cannot have or choose not to get a standard transplant.
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
This Phase 2 study tests whether giving azacitidine plus NAC can improve a common complication after blood and marrow transplant (HSCT): persistently low platelets. It aims to see if treatment can help your blood counts recover when platelets stay very low by about day 60 or later.
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.